Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products, Alkindi and Chronocort, are in late-stage clinical trials, with Alkindi already licensed in Europe. With the successful outcome of the Phase I trial with DITEST, an oral testosterone replacement formulation, DNL is building on its vision of becoming a leading speciality endocrinology company. The study showed that DITEST was safe, well tolerated and well absorbed in men affected by hypogonadism. DNL will engage with the regulators for the next trial stage, which is likely to be run with a partner.
If you'd like to be introduced to the team at Diurnal Group Plc, get in touch.Request a meeting